A probabilistic method to report predictions from a human liver microsomes stability QSAR model: a practical tool for drug discovery
暂无分享,去创建一个
Man-Ling Lee | Ignacio Aliagas | Timothy Heffron | Daniel F. Ortwine | Alberto Gobbi | Mark Zak | S. Cyrus Khojasteh | I. Aliagas | A. Gobbi | D. Ortwine | M. Zak | S. C. Khojasteh | Timothy Heffron | Man-Ling Lee
[1] Johan Ulander,et al. Impact of input parameters on the prediction of hepatic plasma clearance using the well-stirred model. , 2010, Current drug metabolism.
[2] BinQing Wei,et al. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. , 2011, Journal of medicinal chemistry.
[3] Li Li,et al. In silico prediction of cytochrome P450-mediated drug metabolism. , 2011, Combinatorial chemistry & high throughput screening.
[4] James G. Nourse,et al. Reoptimization of MDL Keys for Use in Drug Discovery , 2002, J. Chem. Inf. Comput. Sci..
[5] Lemont B. Kier,et al. The E-State as the Basis for Molecular Structure Space Definition and Structure Similarity , 2000, J. Chem. Inf. Comput. Sci..
[6] E. Hodgson,et al. Organophosphorus Chemicals: Potent Inhibitors of the Human Metabolism of Steroid Hormones and Xenobiotics , 2006, Drug metabolism reviews.
[7] M. Forina,et al. Class-modeling techniques, classic and new, for old and new problems , 2008 .
[8] D J Rance,et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.
[9] Douglas R. Henry,et al. Optimization of MDL substructure search keys for the prediction of activity and toxicity , 2005 .
[10] Li Di,et al. Development of QSAR models for microsomal stability: identification of good and bad structural features for rat, human and mouse microsomal stability , 2010, J. Comput. Aided Mol. Des..
[11] Robert P. Sheridan,et al. Similarity to Molecules in the Training Set Is a Good Discriminator for Prediction Accuracy in QSAR , 2004, J. Chem. Inf. Model..
[12] Yvonne C. Martin,et al. Application of Belief Theory to Similarity Data Fusion for Use in Analog Searching and Lead Hopping , 2008, J. Chem. Inf. Model..
[13] David B Duignan,et al. High throughput ADME screening: practical considerations, impact on the portfolio and enabler of in silico ADME models. , 2008, Current drug metabolism.
[14] Hoa Le,et al. Comparison of metabolic soft spot predictions of CYP3A4, CYP2C9 and CYP2D6 substrates using MetaSite and StarDrop. , 2011, Combinatorial chemistry & high throughput screening.
[15] Scott P. Brown,et al. A unified, probabilistic framework for structure- and ligand-based virtual screening. , 2011, Journal of medicinal chemistry.
[16] G. Cruciani,et al. MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. , 2005, Journal of medicinal chemistry.
[17] Barry C. Jones,et al. DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS , 2004, Drug Metabolism and Disposition.
[18] A. Ghose,et al. Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods , 1998 .
[19] M. Jamei,et al. Misuse of the Well-Stirred Model of Hepatic Drug Clearance , 2007, Drug Metabolism and Disposition.
[20] J. Halladay,et al. Metabolic stability screen for drug discovery using cassette analysis and column switching. , 2007, Drug metabolism letters.
[21] P. Hajduk,et al. Cheminformatic tools for medicinal chemists. , 2010, Journal of medicinal chemistry.
[22] Wendy A. Warr,et al. Guiding effective decisions: an interview with Matthew Segall, CEO of Optibrium , 2011, J. Comput. Aided Mol. Des..
[23] Anthony Long,et al. Computer systems for the prediction of xenobiotic metabolism. , 2002, Advanced drug delivery reviews.
[24] Andreas Bender,et al. Computational Prediction of Metabolism: Sites, Products, SAR, P450 Enzyme Dynamics, and Mechanisms , 2012, J. Chem. Inf. Model..
[25] Ralph Kühne,et al. External Validation and Prediction Employing the Predictive Squared Correlation Coefficient Test Set Activity Mean vs Training Set Activity Mean , 2008, J. Chem. Inf. Model..
[26] Sean Ekins,et al. Using Open Source Computational Tools for Predicting Human Metabolic Stability and Additional Absorption, Distribution, Metabolism, Excretion, and Toxicity Properties , 2010, Drug Metabolism and Disposition.
[27] Jean Carletta,et al. Assessing Agreement on Classification Tasks: The Kappa Statistic , 1996, CL.
[28] Ryan H. Lilien,et al. Applying Medicinal Chemistry Transformations and Multiparameter Optimization to Guide the Search for High-Quality Leads and Candidates , 2011, J. Chem. Inf. Model..
[29] Yojiro Sakiyama,et al. Predicting human liver microsomal stability with machine learning techniques. , 2008, Journal of molecular graphics & modelling.
[30] Man-Ling Lee,et al. DEGAS: Sharing and Tracking Target Compound Ideas with External Collaborators , 2012, J. Chem. Inf. Model..
[31] John C. Davis,et al. Significant Species Difference in Amide Hydrolysis of GDC-0834, a Novel Potent and Selective Bruton's Tyrosine Kinase Inhibitor , 2011, Drug Metabolism and Disposition.
[32] David Rogers,et al. Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..
[33] Jane R Kenny,et al. Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2. , 2012, Journal of medicinal chemistry.
[34] Supa Hannongbua,et al. In-silico ADME models: a general assessment of their utility in drug discovery applications. , 2011, Current topics in medicinal chemistry.
[35] Jing Lu,et al. Development of in silico models for human liver microsomal stability , 2007, J. Comput. Aided Mol. Des..
[36] G R Wilkinson,et al. Commentary: a physiological approach to hepatic drug clearance. , 1975, Clinical pharmacology and therapeutics.
[37] Shane Weaver,et al. The importance of the domain of applicability in QSAR modeling. , 2008, Journal of molecular graphics & modelling.
[38] J B Houston,et al. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.
[39] Grant R. Wilkinson,et al. A physiological approach to hepatic drug clearance , 1975 .
[40] Gunnar Rätsch,et al. Active Learning with Support Vector Machines in the Drug Discovery Process , 2003, J. Chem. Inf. Comput. Sci..
[41] Jan M. Kriegl,et al. Computational approaches to predict drug metabolism , 2009, Expert opinion on drug metabolism & toxicology.
[42] Glenn Shafer,et al. A Mathematical Theory of Evidence , 2020, A Mathematical Theory of Evidence.
[43] Jane R Kenny,et al. Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2. , 2013, Journal of medicinal chemistry.
[44] Bohdan Waszkowycz,et al. Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors. , 2012, Journal of medicinal chemistry.
[45] Ovidiu Ivanciuc,et al. Applications of Support Vector Machines in Chemistry , 2007 .
[46] Gary Box,et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . , 2008, Journal of medicinal chemistry.